TRAF3 and cardiomyopathy: These results suggested that in doxorubicin-induced cardiomyopathy, upregulated TRAF3 may bind to TAK1 and promote its phosphorylation, thereby inducing downstream activation of JNK, P38 MAPK, ERK and eliciting doxorubicin cardiotoxicity.